# Being attack-free is associated with improved quality of life for patients with hereditary angioedema treated with garadacimab: Post hoc analysis from the pivotal Phase 3 (VANGUARD) study


E. Aygören-Pürsün,¹ P. Staubach,² T. J. Craig,³,⁴ T. Fukuda,⁵ R. Hakl,⁶,⁷ J. Braverman,˚ J-P. Lawo,⁶ M. Pollen,˚ C. Nenci,¹º P. Li,¹¹ H. Farkas¹²

1 Rlinikum der Johann Wolfgang-Goethe University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Pediatrics and Biomedical Sciences, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Penn State University, Hershey, PA, USA; Winmec International of Medicine, Penn State University, Penn State Universit umology, St. Anne's University, Baitama Medical University, Baitama Medical University, Saitama Medical University, Saitama, Japan; Ecsl. Behring, King of Prussia, PA, USA; Csl. Behring Innovation Wedical University, Saitama Medical University, Saitama Medical University, Saitama Medical University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Japan; Department of Clinical Immunology, St. Anne's University, Saitama, Sait GmbH, Marburg, Germany; 10CSL Behring AG, Bern, Switzerland; 11Division of Rheumatology, Hungarian Angioedema Center of Reference and Excellence, Semmelweis University, Budapest, Hungary. 12Department of Medicine and Haematology, Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 12Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 12Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Hungary. 13Department of Medicine and Excellence, Semmelweis University, Budapest, Medicine and Excellence, Budapest, Hungary. 13Department of Medicine and Excellence, Budapest, Medicine and Budapest, Medicine and Excellence, Budapest, Medicine and Budapest,

#### HAE AND GARADACIMAB<sup>1-4</sup>

- HAE attacks are detrimental to HRQoL and potentially life-threatening<sup>1,2</sup>
- Need for improved treatments to enhance disease control and "normalize" life<sup>1,2</sup>
- Garadacimab is a first-in-class, fully human mAb targeting FXIIa under evaluation for HAE in pediatric, adolescent, and adult patients<sup>3–5</sup>

### STUDY DESIGN AND KEY OUTCOMES OF THE PIVOTAL PHASE 3 (VANGUARD) STUDY



87% Reduction in mean monthly number of HAE attacks vs placebo, P<0.0001 (median reduction 100%; exposure 6 months)

**62%** Attack-free for 6 months vs 0% with placebo

\*Defined as ≥50% relative reduction in the time-normalized number of HAE attacks.<sup>7</sup>


#### **FOCUS OF THIS PRESENTATION**

#### **POST HOC ANALYSIS FROM THE PIVOTAL PHASE 3 STUDY**

HRQoL per AE-QoL at Day 182 in patients who were attack-free vs placebo and those with ≥1 attack vs placebo

Garadacimab

### GARADACIMAB IMPROVED HRQOL VS PLACEBO





AE-QoL MCID reached by 88% patients with garadacimab vs 55% with placebo, nominal P=0.004

MCID: ≥6 point improvement from baseline<sup>8</sup>

\*Data are presented for patients with available AE-QoL data at Day 1 and Day 182; no patients receiving placebo remained attack-free.







\*Data are presented for patients with available AE-QoL data at Day 1 and Day 182; no patients receiving placebo remained attack-free; †Sum of AE-QoL total scores may exceed 100 due to rounding.



Garadacimab

95% Responders\* vs 33% with placebo

Placebo


Favorable safety and

Clinically meaningful HRQoL

Day 31, sustained to Day 182

improvements as early as

tolerability profiles



## CONCLUSIONS

- Garadacimab leads to substantial HRQoL improvement vs placebo
- The greatest HRQoL improvements vs placebo are observed with patients receiving garadacimab who are attack-free

